NASDAQ:XOMA XOMA Royalty (XOMA) Stock Price, News & Analysis $41.72 +0.07 (+0.17%) As of 05/26/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About XOMA Royalty Stock (NASDAQ:XOMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XOMA Royalty alerts:Sign Up Key Stats Today's Range$41.55▼$41.7650-Day Range$26.61▼$42.0052-Week Range$22.29▼$42.81Volume67,599 shsAverage Volume240,361 shsMarket Capitalization$523.17 millionP/E Ratio26.57Dividend YieldN/APrice Target$53.75Consensus RatingHold Company Overview XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders. The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways. Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.AI Generated. May Contain Errors. Read More XOMA Royalty Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreXOMA MarketRank™: XOMA Royalty scored higher than 68% of companies evaluated by MarketBeat, and ranked 244th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingXOMA Royalty has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on no strong buy ratings, 1 buy rating, 6 hold ratings, and no sell ratings.Upside PotentialXOMA Royalty has a consensus price target of $53.75, representing about 28.8% upside from its current price of $41.72.Amount of Analyst CoverageXOMA Royalty has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about XOMA Royalty's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth-26.60% Earnings GrowthEarnings for XOMA Royalty are expected to decrease by -26.60% in the coming year, from $0.94 to $0.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA Royalty is 26.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.84.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA Royalty is 26.57, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.07.Price to Book Value per Share RatioXOMA Royalty has a P/B Ratio of 5.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about XOMA Royalty's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.75% of the float of XOMA Royalty has been sold short.Short Interest Ratio / Days to CoverXOMA Royalty has a short interest ratio ("days to cover") of 1.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XOMA Royalty has recently decreased by 31.51%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXOMA Royalty does not currently pay a dividend.Dividend GrowthXOMA Royalty does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.22 News SentimentXOMA Royalty has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for XOMA Royalty this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for XOMA on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows2 people have added XOMA Royalty to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XOMA Royalty insiders have not sold or bought any company stock.Percentage Held by Insiders8.90% of the stock of XOMA Royalty is held by insiders.Percentage Held by Institutions95.92% of the stock of XOMA Royalty is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XOMA Royalty's insider trading history. Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA Royalty and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XOMA Stock News HeadlinesSaying Goodbye To The XOMA Royalty PFDsMay 25 at 8:11 AM | seekingalpha.comXOMA Royalty Advances Merger Plans and Governance ChangesMay 22, 2026 | tipranks.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day. | Brownstone Research (Ad)XOMA Royalty (NASDAQ:XOMA) Shares Cross Above Two Hundred Day Moving Average - Here's WhyMay 20, 2026 | americanbankingnews.comLigand Pharma Advances XOMA Royalty Acquisition with AmendmentMay 18, 2026 | tipranks.comXOMA Royalty amends merger agreement with Ligand PharmaceuticalsMay 18, 2026 | tipranks.comA Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta TerminationMay 12, 2026 | finance.yahoo.comXOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMAApril 28, 2026 | tmcnet.comSee More Headlines XOMA Stock Analysis - Frequently Asked Questions How have XOMA shares performed this year? XOMA Royalty's stock was trading at $26.59 at the start of the year. Since then, XOMA stock has increased by 56.9% and is now trading at $41.72. How were XOMA Royalty's earnings last quarter? XOMA Royalty Corporation (NASDAQ:XOMA) issued its quarterly earnings results on Tuesday, May, 12th. The biotechnology company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.19 by $0.02. The biotechnology company earned $12.32 million during the quarter, compared to the consensus estimate of $13.91 million. XOMA Royalty had a net margin of 53.46% and a trailing twelve-month return on equity of 12.56%. Who are XOMA Royalty's major shareholders? XOMA Royalty's top institutional shareholders include Dimensional Fund Advisors LP (1.12%), Bank of New York Mellon Corp (0.63%), Bank of America Corp DE (0.09%) and Royal Bank of Canada (0.01%). Insiders that own company stock include Bvf Partners L P/Il, Owen Hughes, Thomas M Burns, Joseph M Limber and Bradley Sitko. View institutional ownership trends. How do I buy shares of XOMA Royalty? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XOMA Royalty own? Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA Royalty investors own include American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/12/2026Today5/26/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 XOMA's financial health is in the Green zone, according to TradeSmith. XOMA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMA CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees10Year Founded1981Price Target and Rating Average Price Target for XOMA Royalty$53.75 High Price Target$76.00 Low Price Target$39.00 Potential Upside/Downside+28.8%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$1.57 Trailing P/E Ratio26.57 Forward P/E Ratio44.38 P/E GrowthN/ANet Income$31.71 million Net Margins53.46% Pretax Margin69.85% Return on Equity12.56% Return on Assets4.11% Debt Debt-to-Equity Ratio0.96 Current Ratio3.59 Quick Ratio3.59 Sales & Book Value Annual Sales$52.15 million Price / Sales10.03 Cash Flow$0.57 per share Price / Cash Flow73.05 Book Value$7.40 per share Price / Book5.64Miscellaneous Outstanding Shares12,540,000Free Float11,425,000Market Cap$523.17 million OptionableOptionable Beta0.90 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:XOMA) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
